- Home
- BAP vs WAT Comparison
BAP vs WAT Comparison
Compare BAP & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAP
- WAT
- Stock Information
- Founded
- BAP 1889
- WAT 1958
- Country
- BAP Peru
- WAT United States
- Employees
- BAP N/A
- WAT N/A
- Industry
- BAP Major Banks
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- BAP Finance
- WAT Industrials
- Exchange
- BAP Nasdaq
- WAT Nasdaq
- Market Cap
- BAP 21.1B
- WAT 17.4B
- IPO Year
- BAP 1995
- WAT 1995
- Fundamental
- Price
- BAP $258.85
- WAT $387.37
- Analyst Decision
- BAP Buy
- WAT Buy
- Analyst Count
- BAP 6
- WAT 13
- Target Price
- BAP $245.00
- WAT $379.00
- AVG Volume (30 Days)
- BAP 227.4K
- WAT 637.6K
- Earning Date
- BAP 11-13-2025
- WAT 11-04-2025
- Dividend Yield
- BAP 4.26%
- WAT N/A
- EPS Growth
- BAP 26.90
- WAT 3.82
- EPS
- BAP 22.19
- WAT 10.88
- Revenue
- BAP $5,576,317,301.00
- WAT $3,105,638,000.00
- Revenue This Year
- BAP $24.87
- WAT $7.12
- Revenue Next Year
- BAP $7.51
- WAT $6.22
- P/E Ratio
- BAP $11.67
- WAT $35.50
- Revenue Growth
- BAP 20.05
- WAT 6.90
- 52 Week Low
- BAP $165.51
- WAT $275.05
- 52 Week High
- BAP $280.88
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- BAP 49.56
- WAT 77.28
- Support Level
- BAP $255.00
- WAT $340.09
- Resistance Level
- BAP $263.08
- WAT $382.02
- Average True Range (ATR)
- BAP 4.66
- WAT 10.44
- MACD
- BAP 0.16
- WAT 2.22
- Stochastic Oscillator
- BAP 48.80
- WAT 99.09
About BAP Credicorp Ltd.
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.